Effects of Ambrisentan in a Patient Affected by Combined Pulmonary Fibrosis and Emphysema and by Severe Pulmonary Hypertension: Clinical, Functional, and Biomolecular Findings
Tóm tắt
Combined pulmonary fibrosis and emphysema (CPFE) is a computed tomography (CT)-defined syndrome of combined pulmonary fibrosis and emphysema, characterized by subnormal spirometry, impairment of gas exchange, and high prevalence of pulmonary hypertension. Although endothelin-1 (ET-1) plays an important role in the development of lung fibrosis as well as in pulmonary hypertension, no ET-1-targeted therapy is currently recommended. Here we report a case of CPFE successfully treated with ambrisentan, an endothelin-A receptor antagonist, and also discuss the biologic mechanisms underlying the observed therapeutic effects. A 79-year-old man with chronic obstructive pulmonary disease (COPD) was referred to our respiratory unit as an outpatient for dyspnea. Clinical, radiologic, and laboratory findings suggested a diagnosis of chronic hypoxemic, type 1 respiratory failure, due to combined pulmonary fibrosis and emphysema, complicated by severe, precapillary pulmonary hypertension. Pharmacologic treatment with ambrisentan induced an initial improvement in clinical symptoms that proved to be very relevant 9 months later. In order to investigate the biologic mechanisms underlying the clinical effects of ambrisentan, we performed an “in vitro” study on primary cultures of fibrotic human lung fibroblasts, as well as on human umbilical vein endothelial cells, incubated for 24 and 48 h with ET-1, in the absence or presence of an overnight treatment with ambrisentan. ET-1 significantly increased cell proliferation and mitogen-activated protein kinase activation (P < 0.01). These effects were significantly (P < 0.01) inhibited by ambrisentan in both cell cultures. In conclusion, we hypothesize that the clinical benefits induced by ambrisentan in this patient with CPFE can be attributed to its vasodilator and anti-proliferative actions, exerted on pulmonary the vascular bed and lung fibroblasts.
Tài liệu tham khảo
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–93.
Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest. 2009;136(1):1–2.
Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136:10–5.
Rossi F, Gallelli L, Marrocco G, et al. Ruolo dell’endotelina nell’apparato respiratorio. Minerva Pneumol. 2000;39:111–22.
Pelaia G, Gallelli L, D’Agostino B, et al. Effects of TGF-beta and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. J Cell Physiol. 2007;210:489–97.
Gallelli L, Falcone D, Pelaia G, et al. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts. Cell Prolif. 2008;41:393–407.
Pelaia G, Gallelli L, Renda T, et al. Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non small lung cancer cells. Cell Prolif. 2012;45:557–65.
Pelaia G, Cuda G, Vatrella A, et al. Effects of hydrogen peroxide on MAPK activation, IL-8 production and cell viability in primary cultures of human bronchial epithelial cells. J Cell Biochem. 2004;93(1):142–52.
Gallelli L, Pelaia G, Fratto D, et al. Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells. Int J Immunopathol Pharmacol. 2010;23:471–9.
Falcone D, Gallelli L, Di Virgilio A, et al. Effects of simvastatin and rosuvastatin on matrix metalloproteinase 9 and NF-kB in lung cancer and in normal pulmonary tissues. Cell Prolif. 2013;46:172–82.
Preiano M, Pasqua L, Gallelli L, et al. Simultaneous extraction and rapid visualization of peptidomic and lipidomic body fluids fingerprints by using mesoporous aluminosilicate and MALDI-TOF MS. Proteomics. 2012;12:3286–94.
Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63:295–304.
Cottin V, Le Pavec J, Mal H, et al. Combined pulmonary fibrosis and emphysema with associated pulmonary hypertension: characteristics and prognostic determinants. Am J Respir Crit Care Med. 2009;179:A4926.
Boniface S, Reynaud-Gaubert M. Endothelin receptor antagonists—their role in pulmonary medicine. Rev Mal Respir. 2011;28:e94–107.
Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;44:1–10.
Weil BR, Westby CM, Greiner JJ, et al. Elevated endothelin-1 vasoconstrictor tone in prehypertensive adults. Can J Cardiol. 2012;28(3):347–53.
D’Agostino B, Advenier C, Falciani M, et al. Endothelin-1 increases cholinergic nerve-mediated contraction of human bronchi via tachykinin synthesis induction. Br J Pharmacol. 2001;134:1447–54.
Kuhlmann CR, Most AK, Li F, et al. Endothelin-1-induced proliferation of human endothelial cells depends on activation of K+ channels and Ca[2]+ influx. Acta Physiol Scand. 2005;183(2):161–9.
Gallelli L, Pelaia G, D’Agostino B, et al. Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ET(A) receptor-dependent activation of MAP kinases. J Cell Biochem. 2005;96(4):858–68.
Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357–67.
D’Agostino B, Gallelli L, Falciani M, et al. Endothelin-1 induced bronchial hyperresponsiveness in the rabbit: an ET(A) receptor-mediated phenomenon. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:665–9.
Shetty N, Derk CT. Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm Allergy Drug Targets. 2011;10:19–26.